| Nome |
# |
|
Role of interferon lambda 4 and ALT levels in optimising treatment of HCV for patients with low-stage fibrosis, file e2f56ed4-c0a8-3eaf-e053-3a05fe0a5d97
|
590
|
|
Impact of direct-acting antiviral drugs for chronic hepatitis C on mood: Preliminary results from a longitudinal study, file e2f56ed8-50fb-3eaf-e053-3a05fe0a5d97
|
497
|
|
Safety and efficacy of direct-acting antivirals in transfusion-dependent thalassemic patients with chronic hepatitis C, file e2f56ed7-136a-3eaf-e053-3a05fe0a5d97
|
298
|
|
Bone mass preservation with high-dose cholecalciferol and dietary calcium in HIV patients following antiretroviral therapy. Is it possible?, file e2f56ed7-fd0f-3eaf-e053-3a05fe0a5d97
|
269
|
|
Distribution of IL28B polymorphism in a cohort of Italians and immigrants with HCV infection: association with viraemia, stage of fibrosis and response to treatment, file e2f56ed5-3867-3eaf-e053-3a05fe0a5d97
|
219
|
|
Exploring the Role of Killer Cell Immunoglobulin-Like Receptors and Their HLA Class I Ligands in Autoimmune Hepatitis, file e2f56ed4-bff5-3eaf-e053-3a05fe0a5d97
|
215
|
|
Human Leukocyte Antigen Complex and Other Immunogenetic and Clinical Factors Influence Susceptibility or Protection to SARS-CoV-2 Infection and Severity of the Disease Course. The Sardinian Experience, file e2f56ed9-5c39-3eaf-e053-3a05fe0a5d97
|
196
|
|
Review article: safety of new biologic agents for inflammatory bowel disease in the liver, file e2f56eda-0560-3eaf-e053-3a05fe0a5d97
|
195
|
|
Real-life use of elbasvir/grazoprevir in adults and elderly patients: a prospective evaluation of comedications used in the PITER cohort, file e2f56ed9-5b54-3eaf-e053-3a05fe0a5d97
|
164
|
|
Gastrointestinal Coronavirus disease 2019: epidemiology, clinical features, pathogenesis, prevention, and management, file e2f56ed9-8614-3eaf-e053-3a05fe0a5d97
|
164
|
|
HepaDisk – A new quality of life questionnaire for HCV patients, file e2f56ed8-b615-3eaf-e053-3a05fe0a5d97
|
146
|
|
Performance of the model for end-stage liver disease score for mortality prediction and the potential role of etiology, file e2f56eda-0e26-3eaf-e053-3a05fe0a5d97
|
120
|
|
The climate in the European Union and the enlarged European Region is a determinant of the COVID-19 case fatality ratio, file e2f56ed9-4fd2-3eaf-e053-3a05fe0a5d97
|
119
|
|
Entropy of human leukocyte antigen and killer-cell immunoglobulin-like receptor systems in immune-mediated disorders: A pilot study on multiple sclerosis, file e2f56ed9-0821-3eaf-e053-3a05fe0a5d97
|
114
|
|
Optimization of hepatitis C virus screening strategies by birth cohort in Italy, file e2f56ed9-4aa7-3eaf-e053-3a05fe0a5d97
|
107
|
|
Incidence of DAA failure and the clinical impact of retreatment in real-life patients treated in the advanced stage of liver disease: Interim evaluations from the PITER network, file e2f56ed7-02bc-3eaf-e053-3a05fe0a5d97
|
105
|
|
Real-life data on potential drug-druginteractions in patients with chronic hepatitis C viral infection undergoing antiviral therapy with interferon-free DAAs in the PITER Cohort Study, file e2f56ed8-85e8-3eaf-e053-3a05fe0a5d97
|
86
|
|
Advanced liver disease outcomes after hepatitis C eradication by human immunodeficiency virus infection in PITER cohort, file e2f56ed9-26eb-3eaf-e053-3a05fe0a5d97
|
77
|
|
HBcAb Positivity Increases the Risk of Severe Hepatic Fibrosis Development in HIV/HCV-Positive Subjects From the ICONA Italian Cohort of HIV-Infected Patients, file e2f56ed9-c2d4-3eaf-e053-3a05fe0a5d97
|
65
|
|
Differences in lethality and diffusion of Covid-19 in countries using different kinds of vaccines, file 27c96434-7fc5-4686-ab36-f4c404956dec
|
60
|
|
Evaluation of HIV Transmission Clusters among Natives and Foreigners Living in Italy, file e2f56ed9-81fb-3eaf-e053-3a05fe0a5d97
|
59
|
|
The double-sided of human leukocyte antigen-G molecules in type 1 autoimmune hepatitis, file b00c257b-23a3-4c0b-a024-764d5c320771
|
57
|
|
Solid Organ Transplantation During COVID-19 Pandemic: An International Web-based Survey on Resources’ Allocation, file e2f56ed9-c12b-3eaf-e053-3a05fe0a5d97
|
57
|
|
Awareness, discussion and non-prescribed use of HIV pre-exposure prophylaxis among persons living with HIV/AIDS in Italy: a Nationwide, cross-sectional study among patients on antiretrovirals and their treating HIV physicians, file e2f56ed7-1959-3eaf-e053-3a05fe0a5d97
|
56
|
|
Liver function following hepatitis C virus eradication by direct acting antivirals in patients with liver cirrhosis: data from the PITER cohort, file e2f56ed9-cb42-3eaf-e053-3a05fe0a5d97
|
56
|
|
COVID-19 Vaccine Hesitancy among Italian Healthcare Workers: Latent Profiles and Their Relationships to Predictors and Outcome, file 19b46ccc-3a30-46d9-aec2-3934ab4527b6
|
54
|
|
Neutralizing Antibodies Responses against SARS-CoV-2 in a Sardinian Cohort Group Up to 9 Months after BNT162b2 Vaccination, file e2f56eda-702c-3eaf-e053-3a05fe0a5d97
|
48
|
|
A review of the main genetic factors influencing the course of COVID-19 in Sardinia: the role of human leukocyte antigen-G, file a8ad3af2-2038-446b-b2fd-f0e3f0503d1c
|
42
|
|
Management of liver disease in Italy after one year of the SARS-CoV-2 pandemic: A web-based survey, file e2f56eda-0561-3eaf-e053-3a05fe0a5d97
|
42
|
|
Decrease in Incidence Rate of Hospitalizations Due to AIDS-Defining Conditions but Not to Non-AIDS Conditions in PLWHIV on cART in 2008-2018 in Italy, file e2f56eda-0a27-3eaf-e053-3a05fe0a5d97
|
38
|
|
Evaluation of humoral and cellular response to third dose of BNT162b2 mRNA COVID-19 vaccine in patients treated with B-cell depleting therapy, file 16c4bb46-386a-49f7-a6bf-e306a30cda6d
|
37
|
|
Top-Down Proteomics Detection of Potential Salivary Biomarkers for Autoimmune Liver Diseases Classification, file d96505c3-9d17-4518-914a-a237383aa74a
|
37
|
|
Natural killer-cell immunoglobulin-like receptors trigger differences in immune response to SARS-CoV-2 infection, file e2f56eda-8b72-3eaf-e053-3a05fe0a5d97
|
37
|
|
Trends in chronic hepatitis B virus infection in Italy over a 10-year period: Clues from the nationwide PITER and MASTER cohorts toward elimination, file af820beb-5bc6-4bde-aa07-bda3a395d89e
|
35
|
|
PITER-HCV cohort study as part of the Italian platform for the study of viral hepatitis therapies, file e2f56ed6-ca0b-3eaf-e053-3a05fe0a5d97
|
35
|
|
Evaluation of Antibody Response to Heterologous Prime-Boost Vaccination with ChAdOx1 nCoV-19 and BNT162b2: An Observational Study, file e2f56eda-8be3-3eaf-e053-3a05fe0a5d97
|
35
|
|
A prospective study of direct-acting antiviral effectiveness and relapse risk in HCV cryoglobulinemic vasculitis by the Italian PITER cohort, file e2f56eda-51ce-3eaf-e053-3a05fe0a5d97
|
30
|
|
Previous functional social and behavioral rhythms affect resilience to COVID-19-related stress among old adults, file f77927d2-10cd-4416-b64d-35825935ce93
|
29
|
|
Treatment of chronic hepatitis B: Recommendations from an Italian workshop, file e2f56ed6-d42c-3eaf-e053-3a05fe0a5d97
|
23
|
|
The COVID-19 incidence in Italian regions correlates with low temperature, mobility and PM10 pollution but lethality only with low temperature, file e2f56eda-21ba-3eaf-e053-3a05fe0a5d97
|
23
|
|
A Protective HLA Extended Haplotype Outweighs the Major COVID-19 Risk Factor Inherited From Neanderthals in the Sardinian Population, file e2f56eda-a125-3eaf-e053-3a05fe0a5d97
|
23
|
|
Management of primary biliary cholangitis in the pre-obeticholic acid era, and the rate of non-response to ursodeoxycholic acid (UDCA), in a large real-world cohort of PBC patients in Italy: The CLEO-AIGO database, file e2f56ed8-c44b-3eaf-e053-3a05fe0a5d97
|
18
|
|
Direct-acting antivirals used in HCV-related liver disease do not affect thyroid function and autoimmunity, file 5f5dfbc6-2163-4b58-a1ba-a02d043f71fb
|
17
|
|
Evaluation of antibody response to BNT162b2 mRNA COVID-19 vaccine in patients affected by immune-mediated inflammatory diseases up to 5 months after vaccination, file e2f56eda-7e8b-3eaf-e053-3a05fe0a5d97
|
17
|
|
Decision trees for early prediction of inadequate immune response to coronavirus infections: a pilot study on COVID-19, file f18bfd47-c9fd-44d2-9c43-bac6f10abe9b
|
17
|
|
COVID-19: Considerations about immune suppression and biologicals at the time of SARS-CoV-2 pandemic, file e2f56eda-2959-3eaf-e053-3a05fe0a5d97
|
16
|
|
Is the Inversion in the Trend of the Lethality of the COVID-19 in the Two Hemispheres due to the Difference in Seasons and Weather?, file e2f56ed9-938a-3eaf-e053-3a05fe0a5d97
|
15
|
|
Economic Consequences of Anti-HCV Treatment of Patients Diagnosed Through Screening in Italy: A Prospective Modelling Analysis, file e2f56eda-6dda-3eaf-e053-3a05fe0a5d97
|
14
|
|
Impact of Exposure to Vaccination and Infection on Cellular and Antibody Response to SARS-CoV-2 in CVID Patients Through COVID-19 Pandemic, file 448e2ed8-cf19-4774-9d91-5690ab42bf09
|
11
|
|
Comparing the responses of countries
and National Health Systems
to the COVID-19 pandemic:
a critical analysis with a case-report series, file 8593ac91-8e25-4f2a-9edd-ee03aef561dd
|
11
|
|
Forecasting liver disease burden, file e2f56ed7-6080-3eaf-e053-3a05fe0a5d97
|
11
|
|
L'Italia come modello per l'Europa e per il mondo nelle politiche sanitarie per il trattamento dell'epatite cronica da HCV Gruppo, file e2f56ed7-fac2-3eaf-e053-3a05fe0a5d97
|
11
|
|
Role of natural killercells receptors on the development and progression of hepatocellularcarcinoma, file e2f56ed8-92f6-3eaf-e053-3a05fe0a5d97
|
11
|
|
Impact of HCV eradication on lipid metabolism in HIV/HCV coinfected patients: Data from ICONA and hepaICONA foundation cohort study, file e2f56eda-29c7-3eaf-e053-3a05fe0a5d97
|
11
|
|
Real-world data on the treatment of primary biliary cholangitis with obeticholic acid in Italy: the CLEO-AIGO OCA cohort., file e2f56ed9-1f50-3eaf-e053-3a05fe0a5d97
|
10
|
|
Genetic determinants in a critical domain of ns5a correlate with hepatocellular carcinoma in cirrhotic patients infected with hcv genotype 1b, file e2f56ed9-ee79-3eaf-e053-3a05fe0a5d97
|
10
|
|
HLA-G is highly expressed by plasma cells infiltrating hepatic tissue of patients affected by autoimmune hepatitis, file e2f56ed6-d0ed-3eaf-e053-3a05fe0a5d97
|
9
|
|
Clinical features and comorbidity pattern of HCV infected migrants compared to native patients in care in Italy: A real-life evaluation of the PITER cohort, file e2f56eda-262e-3eaf-e053-3a05fe0a5d97
|
9
|
|
Predictors of serious adverse events and non-response in cirrhotic patients with primary biliary cholangitis treated with obeticholic acid, file e3262419-d9b6-4046-9961-cfc6370c30a4
|
9
|
|
Humoral responses to wild type and ancient BA.1 SARS-CoV-2 variant after heterologous priming vaccination with ChAdOx1 nCoV-19 and BNT162b2 booster dose, file c68a0dec-03d7-48d6-a7eb-4e5a3fc5fac1
|
8
|
|
Combination of IFNL4 polymorphisms and ALT reduction at 4 week of treatment with PEG IFN and Ribavirin is a new selection tool to optimize antiviral treatment allocation in HCV patients with low stage fibrosis, file e2f56ed4-7984-3eaf-e053-3a05fe0a5d97
|
8
|
|
INFLUENZA DEI POLIMORFISMI DELL’INTERFERONE LAMBDA NELLA STORIA NATURALE DELLA INFEZIONE CRONICA DA HBV: COINCIDENZA O REALTÀ?, file e2f56ed4-7f85-3eaf-e053-3a05fe0a5d97
|
8
|
|
Hippocampal axis dysfunction evaluation by Rey-Osterrieth Complex figure test (RCFT) should be included in minimal hepatic encephalopathy (MHE) assessment, file e2f56ed5-8d4a-3eaf-e053-3a05fe0a5d97
|
8
|
|
EFFICACY, SAFETY AND IMPACT ON QUALITY OF LIFE OF A TREATMENT WITH SORAFENIB IN ELDERLY CANCER PATIENTS WITH ADVANCED HEPATOCELLULAR CARCINOMA. RESULTS OF A PHASE II STUDY, file e2f56ed3-967f-3eaf-e053-3a05fe0a5d97
|
7
|
|
Economic Consequences of Investing in Anti-HCV Antiviral Treatment from the Italian NHS Perspective: A Real-World-Based Analysis of PITER Data, file e2f56ed8-3489-3eaf-e053-3a05fe0a5d97
|
7
|
|
Performance of the model for end-stage liver disease score for mortality prediction and the potential role of etiology, file e2f56ed9-d08b-3eaf-e053-3a05fe0a5d97
|
7
|
|
null, file ac2fe9c6-c947-4758-80b9-ab0a9b4c5a25
|
6
|
|
null, file e2f56ed3-91a3-3eaf-e053-3a05fe0a5d97
|
6
|
|
Gender differences in HCV chronic liver disease: a reallife evaluation in PITER (PIATTAFORMA ITALIANA PER LO STUDIO DELLA TERAPIA DELLE EPATITI VIRALI) Cohort study., file e2f56ed5-913d-3eaf-e053-3a05fe0a5d97
|
6
|
|
EVALUATION OF MILD COGNITIVE DYSFUNCTION BY MONTREAL COGNITIVE ASSESSMENT TEST IN PATIENTS WITH CHRONIC HCV INFECTION, file e2f56ed5-fe8f-3eaf-e053-3a05fe0a5d97
|
6
|
|
Diagnostic and therapeutic approaches of mixed cryoglobulinemia in PITER (Piattaforma Italiana per lo studio della Terapia delle Epatiti viRali) cohort, file e2f56ed6-ca5c-3eaf-e053-3a05fe0a5d97
|
6
|
|
Association of chronic hepatitis C with recurrent brief depression, file e2f56ed3-c300-3eaf-e053-3a05fe0a5d97
|
5
|
|
Health gains and costs of HCV treatment: a cost effectiveness analysis of two different health policies scenarios simulated in PITER (Piattaforma Italiana per lo studio della Terapia delle Epatiti viRali) real life cohort, file e2f56ed6-0064-3eaf-e053-3a05fe0a5d97
|
5
|
|
Altered profile of salivary proteins in patients with Autoimmune Hepatitis, file e2f56ed6-ce8a-3eaf-e053-3a05fe0a5d97
|
5
|
|
Modeling cost-effectiveness and health gains of a âuniversalâ versus âprioritizedâ hepatitis C virus treatment policy in a real-life cohort, file e2f56ed7-00e3-3eaf-e053-3a05fe0a5d97
|
5
|
|
Multicenter prospective study of angiogenesis polymorphism validation in HCC patients treated with sorafenib. An Innovate study protocol, file e2f56ed7-bf94-3eaf-e053-3a05fe0a5d97
|
5
|
|
Rate of non-response to ursodeoxycholic acid in a large real-world cohort of primary biliary cholangitis patients in Italy, file e2f56ed8-c436-3eaf-e053-3a05fe0a5d97
|
5
|
|
Optimization of Hepatitis C Virus screening strategies by birth cohort in Italy, file e2f56ed8-fb3b-3eaf-e053-3a05fe0a5d97
|
5
|
|
Treatment prioritization according to the EASL HCV CPG 2015: a real-life evaluation on the PITER (Piattaforma Italiana per lo studio della Terapia delle Epatiti viRali) cohort, file e2f56ed4-797f-3eaf-e053-3a05fe0a5d97
|
4
|
|
FATTORI IMPLICATI NELLA STORIA NATURALE DELL'INFEZIONE DA VIRUS DELTA:IL RUOLO DEGLI INTERFERONI, file e2f56ed4-7b4e-3eaf-e053-3a05fe0a5d97
|
4
|
|
HCV-related mixed cryoglobulinemia: Data from PITER, a nationwide Italian HCV cohort study, file e2f56ed5-868b-3eaf-e053-3a05fe0a5d97
|
4
|
|
Evaluation of mild cognitive dysfunction by Montreal Cognitive Assessment test in patients with chronic HCV infection treated with direct antiviral agents, file e2f56ed6-ca1f-3eaf-e053-3a05fe0a5d97
|
4
|
|
Impact of natural killer (NK) cells receptors gene haplotypes on the development of hepatocarcinoma in cirrhotic patients, file e2f56ed6-cb04-3eaf-e053-3a05fe0a5d97
|
4
|
|
Clinical characterization and economic impact evaluation of antiHCV DAA treatment failure:real life data from the Italian Platform for the Study of Viral Hepatitis Therapies (PITER), file e2f56ed6-cc85-3eaf-e053-3a05fe0a5d97
|
4
|
|
Premature ovarian senescence and a high miscarriage rate impair fertility in women with HCV, file e2f56ed7-02e3-3eaf-e053-3a05fe0a5d97
|
4
|
|
Real life clinical outcomes in DAA-treatedand untreated patients with HCV advanced liver disease. Interim one year data from the ongoing PITER cohort, file e2f56ed7-5d2d-3eaf-e053-3a05fe0a5d97
|
4
|
|
Add-on peginterferon alfa-2a to nucleos(t)ide analogue therapy for Caucasian patients with hepatitis B 'e' antigen-negative chronic hepatitis B genotype D, file e2f56ed8-32c8-3eaf-e053-3a05fe0a5d97
|
4
|
|
Combined Salivary Proteome Profiling and Machine Learning Analysis Provides Insight into Molecular Signature for Autoimmune Liver Diseases Classification, file 0fdef99e-cd60-4056-b892-346c44d110e9
|
3
|
|
Top-Down Proteomics Detection of Potential Salivary Biomarkers for Autoimmune Liver Diseases Classification, file 68ce6eae-28d4-4fe2-bb92-81d20f71b27c
|
3
|
|
Absence of activating killer immunoglobulin-like receptor genes combined with hepatitis C viral genotype is predictive of hepatocellular carcinoma, file e2f56ed3-b230-3eaf-e053-3a05fe0a5d97
|
3
|
|
Killer cell immunoglobulin-like receptors and their HLA class I ligands in autoimmune hepatitis: a possible pathogenetic role ?, file e2f56ed4-7f87-3eaf-e053-3a05fe0a5d97
|
3
|
|
Ombitasvir, paritaprevir, and ritonavir, with or without dasabuvir, plus ribavirin for patients with hepatitis C virus genotype 1 or 4 infection with cirrhosis (ABACUS): a prospective observational study, file e2f56ed6-cd73-3eaf-e053-3a05fe0a5d97
|
3
|
|
La Piattaforma Italiana per lo studio della Terapia delle Epatiti Virali (PITER): il primo grande studio nazionale sull'infezione cronica da virus dell'epatite C, file e2f56ed7-3766-3eaf-e053-3a05fe0a5d97
|
3
|
|
Predictive Factors for Liver Disease Progression Following the Direct Acting Antivirals Induced Sustained Virological Response: Data from the Italian Platform for the Study of Viral Hepatitis Therapies (PITER) Cohort, file e2f56ed7-b4c4-3eaf-e053-3a05fe0a5d97
|
3
|
|
Forecasting liver disease burden based on a real life cohort of the linked to care patients in Italy. Does the ‘underwater portion of the iceberg’ matter to reach the WHO HCV eliminating goals in the high HCV prevalent countries?, file e2f56ed7-c966-3eaf-e053-3a05fe0a5d97
|
3
|
|
Effectiveness and safety of glecaprevir/pibrentasvir in chronic hepatitis C patients: Results of the Italian cohort of a post-marketing observational study, file e2f56ed9-4e76-3eaf-e053-3a05fe0a5d97
|
3
|
|
Impact of Exposure to Vaccination and Infection on Cellular and Antibody Response to SARS-CoV-2 in CVID Patients Through COVID-19 Pandemic, file c4bdd28f-1f59-47d1-956a-970e548dfad6
|
2
|
|
HCV treatment in Sardinian HIV-HCV coinfected patients: a real-life perspective study on safety, efficacy, and immune reconstitution, file c9144203-592e-4c3b-85a9-ca730ef574c1
|
2
|
|
Can antiretroviral therapy modify the clinical course of HDV infection in HIV positive patients?, file e2f56ed3-8aec-3eaf-e053-3a05fe0a5d97
|
2
|
|
The prevalence of bright liver echo pattern in patients with chronic hepatitis C: correlation with steatosis and fibrosis, file e2f56ed5-391f-3eaf-e053-3a05fe0a5d97
|
2
|
| Totale |
5.075 |